How many eggs does a woman have? At birth, 30s, and menopause – Medical News Today

Females are born with all the eggs they will ever have in their lifetime. The amount decreases until a person stops ovulating and reaches menopause.

A females egg quality and quantity determine their likelihood of conceiving. Unlike other cells in the body, egg cells cannot regenerate.

A persons life stage and the presence of various health conditions also affect the number and quality of their eggs.

This article explores how many eggs a female has and their role at different stages of their life. We also discuss tests to measure egg count, fertility options, conditions that may impact eggs, and more.

While females have millions of eggs in their ovaries, they do not mature until puberty. Puberty begins when the hypothalamus, an area of the brain that plays a role in hormone production, produces the gonadotropin-releasing hormone (GnRH).

Menstruation typically begins when a female is 1213 years old. However, some may start as early as 8 years old.

A female typically has around 300,000500,000 eggs when puberty begins and rapidly loses more eggs each month. Aside from their monthly cycles, many factors affect how many eggs a person loses every cycle.

The GnRH regulates the onset of puberty, sexual development, egg development, and ovulation by signaling the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH).

The FSH activates several immature eggs in fluid-filled sacs called follicles to mature during each menstrual cycle. Known as the follicular phase, this process begins on the first day of a persons period.

The ovulation phase begins when the LH stimulates the ovaries to release an egg. However, the ovaries are programmed to allow only one egg to fully mature and be released each cycle. The body reabsorbs the rest.

The chance of fertilization is dependent on the release of a mature egg from the ovary in a particular menstrual cycle.

Learn more about ovulation here.

A female is most fertile in their mid-20s, with a 2530% chance of becoming pregnant each month.

ACOG states that a females fertility gradually and significantly drops around age 32. They will have around 120,000 eggs, with a 20% chance of conceiving per cycle.

ACOG further states that a female will experience a rapid decline by age 37, when egg count drops to around 25,000.

According to the Centers for Disease Control and Prevention (CDC), around 1 in 5 couples where the female partner is 3039 years old experience problems conceiving their first child. However, both males and females may experience infertility.

Learn more about fertility in a persons 30s here.

By 40, a females chance of conceiving drops to 5%.

Older females generally have a lower success rate with fertility treatments such as in-vitro fertilization (IVF).

However, more people are successfully conceiving in their 40s. The number of births in women between 4044 years old rose almost continuously from 1985 to 2019. There was a slight decline in birth rates in 2020 across all age groups.

Using eggs donated by younger females increases the chance of success with IVF for older females.

Learn more about having a baby at 40 here.

By the time a female reaches menopause, they may have fewer than 1,000 eggs.

As a person ages, immature eggs become increasingly resistant to the FSH. As the number of viable eggs decreases, the ovaries also begin to produce significantly less estrogen and progesterone.

This leads to menopause, when a persons menstrual cycle ends and they no longer ovulate.

The average age a person reaches menopause in the United States is 52 years. This varies depending on how many eggs a person has at birth and other factors, such as medical conditions and treatment.

Aside from decreasing in number, eggs also drop in quality as a person ages.

A few hours before ovulation, the oocyte divides, resulting in an egg that contains 23 chromosomes. Older age is highly associated with oocyte abnormalities.

These older eggs are more likely to contain abnormal chromosomes. This is why the risk of having a child with Down Syndrome and other abnormalities is higher as a person ages.

This tendency to have extra or missing chromosomes is also responsible for the increased miscarriage and low birth rates among older adult females.

There are tests that a person can take to estimate their egg count.

The antral follicle test involves a medical practitioner using ultrasound to count visible follicles. This gives them an idea of a persons total egg count and how many eggs a person can potentially freeze during one cycle.

The anti-Mullerian hormone (AMH) is a protein hormone produced by special follicular cells. The AMH level in the blood can help healthcare professionals estimate the number of follicles in a persons ovaries, which gives them an idea of their total egg count.

Since AMH levels are stable throughout the menstrual cycle, a doctor can perform this test at any time.

There are several options a person may consider to improve their chances of pregnancy.

Older people or those who have premature ovarian failure (POF) that causes early menopause may consider egg donation. This involves using eggs donated by another female, typically someone in their 20s or early 30s.

In an egg donation cycle, a donor takes medications to stimulate the production of multiple eggs. At the same time, the recipient undergoes hormone therapy to prepare the uterus for pregnancy.

After the donors eggs are fertilized in a laboratory, a doctor places one or more embryos into the recipients uterus.

Individuals who want to delay childbearing may consider preserving their healthy eggs in a process known as egg freezing. A doctor can extract the eggs while the person is younger and use when they want to become pregnant.

The process involves taking medications to stimulate the ovaries to produce multiple eggs. These eggs are retrieved and kept in a laboratory at sub-zero temperatures.

When a person is ready to conceive, a doctor thaws the eggs and injects surviving eggs with a partner or a donors sperm for fertilization.

People with unexplained infertility, or when traditional options have failed, may try more advanced therapies. These can include IVF and superovulation with timed intrauterine insemination (IUI).

In superovulation and IUI, a female takes medications to stimulate the growth of multiple eggs in the ovaries. When the eggs are ready to ovulate, a donor or partners washed sperm is injected directly into the uterus. Sometimes an additional medication is given to stimulate ovulation so that timing is more certain.

In contrast, IVF involves removing a persons egg that a doctor fertilizes with a donor or partners sperm in a laboratory. Once successful in fertilization, the doctor transfers the embryo to the uterus.

Most information about egg supply and fertility options is for cisgender and heterosexual females. However, fertility issues can affect anyone born with ovaries.

A person transitioning to male can freeze their eggs, embryos, or ovarian tissue before hormone therapy or gender-affirmation surgery.

People assigned female at birth (AFAB) and taking the male hormone testosterone may experience amenorrhea, the absence of menstruation due to the hormone suppressing ovulation.

The effect of taking testosterone on egg supply is unclear. But a recent small study found that functional ovarian reserve was preserved in transgender men receiving testosterone therapy over a prolonged period.

A case study from 2020 documented a person taking testosterone who was able to retrieve eggs for freezing. They stopped testosterone treatment for only 24 days around the time of egg stimulation. This compares to cases where hormone treatment ceased for up to 6 months before egg retrieval.

Another case study from 2019 reported a 20-year-old transgender male becoming pregnant 2 months after stopping testosterone therapy.

More research is needed to offer accurate fertility guidance to trans people.

A person wishing to discuss their fertility options before or after transitioning should speak with a medical professional.

Learn more about testosterone therapy and pregnancy here.

Age is the major factor that affects a females egg quality. However, some conditions may also contribute, including:

A 2017 study found that oxidative stress damages oocytes and impairs their fertilization capacity. Smoking, drinking, drug use, and inadequate diet can increase free radicals in the body, damaging the egg.

According to the CDC, medical professionals recommend that females younger than 35 years with no health or fertility issues and regular periods try to conceive for at least 1 year before consulting a doctor. However, females 35 years or older should contact a doctor after 6 months and even sooner for those over 40 years old.

People who have other health issues or circumstances such as irregular periods or have received chemotherapy should also consider discussing their fertility options sooner.

A persons biological clock affects their fertility. Age not only decreases egg quantity but can also affect their quality.

People concerned about their egg supply due to factors such as aging, different priorities, gender-affirming surgery or hormone therapy, or preparation for cancer treatment have several fertility options to consider.

A person should discuss these options with a healthcare professional to determine which options are most suitable.

Read this article:

How many eggs does a woman have? At birth, 30s, and menopause - Medical News Today

Arthur Riggs, Medical Researcher and Major Donor to City of Hope, Dies at 82 – Los Angeles Business Journal

Arthur Riggs, a world-renowned diabetes expert who developed the technology that led to the first human synthetic insulin for the treatment of diabetes and who became a major donor to Duarte-based City of Hope, died March 23 at age 82 after battling cancer, City of Hope announced March 25.

A biotechnology pioneer and a longtime research leader at City of Hope,Riggsserved as director emeritus of Beckman Research Institute and the Arthur Riggs Diabetes & Metabolism Research Institute at City of Hope.

Last year, he publicly gifted $100 million to City of Hope, at which time the diabetes research center there was renamed in his honor. That followed years of donations made quietly behind the scenes that totaled $210 million, bringing his overall donation total of $310 million. He was by far the most prodigious donor in City of Hopes 109-year history.

City of Hope Researcher Arthur Riggs Helped Create Artificial Insulin; Now Emerges as Its Largest Donor

Riggs major scientific discoveries achieved over more than a half-century of research, paving the way for development of the monoclonal antibody therapies that are the foundation of modern treatments for cancer, autoimmune diseases, blindness and a host of other diseases. His breakthrough work in diabetes enabled mass production of insulin for people living with the disease. Today, synthetic insulin is used by hundreds of millions of people.

Riggswas already recognized for his novel research into the inner workings of DNA when he joined City of Hope as a research scientist in 1969. In 1977, his research led to the creation of the first artificially synthesized gene and human protein, the important hormone inhibitor somatostatin, followed not long after by the first ever synthesis of human growth hormone. A year later, he was able to apply this disruptive technology to produce human insulin from bacteria.

We chose insulin because it looked doable, and there was a need, Riggs said in a Business Journal interview last year. At the time, diabetics were being treated with cow insulin because there was no source of human insulin. And cow insulin resulted in a high rate of allergic reactions.

As a scientist and leader at City of Hope over the next 53 years,Riggscontinued to perform groundbreaking research and make major contributions across the life sciences. His 1975 paper on mammalian epigenetics how behaviors and environment can cause changes that affect the way genes work remains one of the most frequently referenced on the subject.

Throughout his long research career, he authored more than 200 scholarly papers and amassed 20 patents. He was recognized for this lifetime of achievements by his election to the National Academy of Sciences in 2006.

ArthurRiggsis one of the scientific giants of the age and should be a household name for his contributions to diabetes alone, Robert Stone, City of Hopes chief executive, said in the announcement of Riggs death. His research also led to the development of monoclonal antibody therapies that today treat cancer and other diseases.

Stone said Riggs also served as a mentor for dozens of City of Hope researchers over the five decades he served there.

City of Hope today owes an enormous debt to him, as do countless people whose lives have been changed by his discoveries, Stone said of Riggs.

Riggs continued his research efforts at City of Hope until just a few months before he died.

I could have retired into a South Pacific mansion and enjoyed myself on the beach, but I would have been bored within a week, he said in the Business Journal interview. Im going to keep going as long as I can. There is such a need for diabetes research and treatment; diabetes is an epidemic, and it is becoming a huge problem for world health.

Read the original post:

Arthur Riggs, Medical Researcher and Major Donor to City of Hope, Dies at 82 - Los Angeles Business Journal

Cryotherapy 101: Explore This Innovative Body Treatment – Orlando Magazine

(BILL FREDETTE-HUFFMAN)

There are a lot of reasons to try cryotherapy: Maybe youre looking to enhance your athletic performance. Maybe youre constantly icing sore body parts. Maybe youre desperately in need of more restorative sleep. Or maybe youre just curious.

I, for one, fell in the latter category. Ive always been willing to try the latest spa treatments, so when I heard about Orlandos Athlete Recovery Room, I couldnt wait to see what cryo was all about. Although, the only thing I knew was that its cold therapy and as a native Floridian, being chilly isnt necessarily something I enjoy.

Luckily, its a dry cold. Its like going into a walk-in freezer but one thats even colder, explains owner Althea Stearns. Stearns, an avid runner whos completed 50 marathons across the world in ten years, began experimenting with cryotherapy to relieve her tired muscles. Id go to big cities and see recovery places, and I was like why dont we have something like this in Orlando? I initially started doing it as a mobile thing and it happened into this, she says.

In February 2020, she officially opened her studios doors on Corrine Drive. While theres a range of available services like massage, infrared sauna sessions, compression therapy, and facials, cryotherapy is one of Athlete Recovery Rooms biggest draws. They use a MECOTEC CRYO:ONE tank which fully immerses the body and head with cold air and oxygen.

So, what exactly does a treatment do? As your body is exposed to the cold, it triggers a fight or flight response, causing the nervous system to have a parasympathetic reaction. The extreme cold aids the body in producing norepinephrine (released predominantly from sympathetic nerve fibers), which acts like a natural pain reliever, says Stearns. Additionally, the cold cues your body to release beta-endorphins, which are proteins primarily synthesized by the pituitary gland. These endorphins play a significant role in the sleep cycle and pain management. Because endorphins act as sedatives, which helps aid in sleep, she furthers. The number one thing athletes need is sleep, because its when the human growth hormone is produced (which helps the body heal and recover from exercise). If you sleep better, then you can perform better.

The Athlete Recovery Room on Corrine Drive offers many treatment options. (BILL FREDETTE-HUFFMAN)

Thats why local athletes like baseball players, MMA fighters, and even student athletes (the studio offers special memberships for them) are constantly coming through the doors. I felt sore a lot, so my dad brought me in to try it out, says Camilia Jones, a local tenth grade volleyball player who visits the Athlete Recovery Room almost daily. Its made me feel a lot better more relaxed, I notice a difference in soreness, and endurance-wise, I can go on a lot more.

However, dont feel like you need to be an athlete to reap the rewards. The cold makes your blood vessels constrict which helps with inflammation itself, says Stearns, which is why its an ideal treatment for sprains, chronic back pain, herniated discs, muscle soreness, and more. If youre really looking to address certain areas, they have a targeted nozzle to direct the cold air to the desired spot. You can even do cryo facials to tighten pores and achieve a lit-from-within glow.

Before a cryotherapy session its imperative to properly prepare. For the best results, wear underwear inside the chamber along with the provided gloves, socks, and an ear-shielding headband (mine even had built in music speakers). Beforehand, someone takes your skins surface temperature twice, once on the back of your shoulder and once on the back of your calf. According to Stearns, you ideally want those numbers to drop twenty-five to thirty degrees for the best results.

The cryotherapy tank was -124 degrees when I entered a.k.a. it was chilly. Thankfully, it wasnt a shocking cold like jumping into an ice bath. By the time the three minutes were up, my temperature dropped 25 degrees. Right on target. As I left, I experienced the post-cryo adrenaline rush I was told about (a much-needed boost of energy for someone with a toddler at home), but physically, I didnt feel much different until the next morning. Thats when I woke up infinitely more rested, and I noticed that my aching back pain had subsided.

One or two sessions are good for temporary relief of soreness, but multiple sessions help the body become a hormone, endorphin, enzyme and antioxidant making machine, explains Stearns. And studies have shown repeated Cryotherapy treatments of 10 or more sessions, will increase white blood cells and glutathione (antioxidant) and enzymes that prevent tissue damage. With results like that, a few minutes of shivering is well worth it.

Continue reading here:

Cryotherapy 101: Explore This Innovative Body Treatment - Orlando Magazine

Ovulation Inducing Drugs Market: Rise in Number of Patients Opting for IVF is Likely to Fuel the Growth Market – BioSpace

Albany NY, United States: Changing lifestyle, medicinal adverse effects, delayed pregnancy, and comorbidities are affecting natural reproduction among the human population. These factors have led to the adoption of in vitro fertilization (IVF) or assisted reproductive treatments across the globe. A womans ovary produces a single egg in a menstrual cycle.

Read Report Overview - https://www.transparencymarketresearch.com/ovulation-inducing-drugs-market.html

In IVF, eggs are extracted and fertilized in a laboratory to create zygotes. These zygotes are then cultured in a controlled environment. On attaining the blastocyst stage, these embryos are then transferred to uterus. Physicians insist on extracting maximum number of eggs due to low volatility and high failure rates in fertilization and other IVF procedures. Various medications including pharmaceutical preparations and hormones are administered to induce ovulation and increase egg count.

Prior to recommending IVF, physicians promote natural pregnancy. In some cases, infertility is even linked to abnormality or deficiency in ovulation or egg production. Ovulation inducing medications augment the chances of pregnancy, as these tend to increase the egg count, thereby increasing fertilization possibilities. Ovulation stimulation is one of the first and critical steps in IVF.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=44964

Rise in number of patients opting for IVF is likely to fuel the growth of the global ovulation inducing drugs market during the forecast period from 2018 to 2026. Moreover, key suppliers are introducing new medications such as recombinant hormones and gonadotropins. This is likely to fuel the growth of the ovulation inducing drugs market. However, high cost of IVF procedure and low success rates are the major factors likely to restrain the global ovulation inducing drugs market. Furthermore, large number of small and medium scale manufacturers of ovulation inducing drugs at regional levels has led to a fragmented ovulation inducing drugs market.

The global ovulation inducing drugs market can be segmented based on drug class, distribution channel, and region. In terms of drug class, the global ovulation inducing drugs market can be bifurcated into hormones and pharmaceuticals. The hormones segment can be classified into follicle stimulating hormone (FSH), human menopausal gonadotropin (hMG), and human chorionic gonadotropin (hCG). hMGs are combination of FSH and luteinizing hormone (LH) offering better efficiency and low adverse effects.

Get COVID-19 Analysis on Ovulation Inducing Drugs Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=44964

The pharmaceuticals segment can be divided into gonadotropin releasing hormone (GnRH) agonists and GnRH antagonists. These drugs stimulate the production of gonadotropin hormones such a FSH and LH to augment the ovulation process. Based on distribution channel, the global ovulation inducing drugs market can be segregated into hospital pharmacies, independent pharmacies, and online pharmacies. In some markets, IVF centers dispense these medications to patients.

In terms of region, the global ovulation inducing drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to account for the largest share of the global ovulation inducing drugs market during the forecast period, due to high adoption of IVF and ART techniques. Europe is anticipated to account for a significant share of the global ovulation inducing drugs market during the forecast period.

Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=44964

Well-established health care infrastructure and trend for fertility tourism in countries in Central and Eastern Europe are the key factors driving the embryo transfer devices market in the region. Increase in expenditure to develop health care infrastructure and rise in private health care expenditure in emerging markets such as China and India are anticipated to boost the market in Asia Pacific. Changing lifestyle and rising rates of infertility are the major factors that contribute to the growth of the ovulation inducing drugs market in developing countries.

Major players operating in the global ovulation inducing drugs market are Sanofi, EMD Serono, Inc., Ferring Pharmaceuticals, Inc., Fresenius Kabi AG, Merck & Co., Inc., Sun Pharmaceuticals Industries Ltd., Serum Institute of India Ltd., and Glenmark Pharmaceuticals Ltd.

Browse more Reports by Transparency Market Research:

Pharmaceutical Excipients Market: The growing bioequivalence sector is flourishing with high prevalence of chronic diseases and increased access to medication, especially through online sales and e-Commerce platforms. Increased R&D spending and emergence of new technologies are bringing about a change in the market for pharmaceutical excipients.

Healthcare Reimbursement Market: Growing patient population, rising prevalence of chronic diseases, initiatives taken by public and private entities, increasing cost of health care which encourages stakeholders interest in reimbursement, and rising awareness among people regarding health insurance policies are driving the global healthcare reimbursement market.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Read more from the original source:

Ovulation Inducing Drugs Market: Rise in Number of Patients Opting for IVF is Likely to Fuel the Growth Market - BioSpace

Jeff Bezos Not Taking HGH, Source

Lots of folks have jumped to the conclusion Jeff Bezos can only get the body we've now seen with the help of human growth hormones -- HGH -- but sources tell TMZ it's all B.S.

The photos of Jeff and girlfriend Lauren Sanchez made people crazy! They're all over St. Barts in the Caribbean ... him without a shirt and revealing a super-jacked bod.

The 57-year-old Amazon titan has been working out like crazy with celeb trainer Wes Okerson. We're told he was on a strict diet and exercise regimen for months.

That said, lots of folks on social media are pooh-poohing Bezos' transformation, chalking it up to HGH.

A source with direct knowledge scoffs at the allegation, telling us the HGH claim is 100% false.

The source insists this is all Jeff and no drugs or other artificial enhancements. A recent report from Page Six says Bezos' trainer is Wesley Okerson, who also apparently was in St. Barts at the same time as Jeff ... so you gotta imagine he's keeping him pumped up.

Lauren apparently like the results on Jeff too, recently posting a pic of the Amazon founder on a paddle board and a "Good job Wes!"

Bezos and Lauren have been ensconced in the Caribbean for more than a week, showing tons of PDA.

Continue reading here:

Jeff Bezos Not Taking HGH, Source

Heartland Group (ASX:HGH) bolsters executive team – The Market Herald

SubscribeBe the first with the news that moves the market

Heartland Group (HGH) has expanded its strategic management group (SMG) to support the companys future growth.

Heartland is a dual-listed financial services company operating in New Zealand and Australia.

The companys services differ slightly in both countries. In New Zealand, the Heartland Bank offers banking products in the household, business and rural markets. In Australia, Heartland specialises in reverse mortgage loans and provides funding to partners within the small business and consumer lending sectors.

As part of Heartlands strategy to enhance its SMG, previous Chief Risk Officer of Heartland Bank Michael Drumm has been appointed as Group Chief Operating Officer of Heartland Group.

Taking his place as Chief Risk Officer of Heartland Bank is Andy Wood, who will assume the role on April 11, 2022.

Heartland said Mr Wood brings 30 years of banking and finance experience and an in-depth knowledge of New Zealands regulatory environment.

Prior to joining Heartland, Mr Wood held several leadership roles at the Reserve Bank of New Zealand (RBNZ).

In his most recent position as Head of Supervision, he was responsible for delivering and modernising the RBNZs overall approach to supervision, covering both prudential and anti-money laundering activities.

Heartland said the changes align with its added focus on Australia and the increased scale in Heartland Bank which requires more dedicated resources.

HGH shares last traded at $2.11 on April 5.

The rest is here:

Heartland Group (ASX:HGH) bolsters executive team - The Market Herald

24/7 Kiln shell temperature monitoring and Process Optimisation at LafargeHolcim Bouskoura plant, Morocco, using HGH thermography solutions – World…

Plant operators need real-time and continuous monitoring of the kiln shell temperature in order to be alerted in case a hot spot occurs. Kilnscan monitors the temperature from an external point of view with a unique reference pyrometer for unsurpassed accuracy in adverse weather conditions. Whereas Pyroscan looks at the kiln from the inside to optimise the clinker calcination process and provides the visualisation of clinker chute. Pyroscan helps operators to stabilise the burner settings, and to improve the clinker sintering process.

HGHs bundle solution comprising an IR scanner and camera meets the clients requirements in terms of high performance.

Amine Mnaouer, Plant Maintenance Manager at LafargeHolcim cement plant said: The use of the HGH scanner brings great added value for the management of the clinker manufacturing process as well as the prevention of any incident of the kiln shell. It is an essential tool for the good operation of the kiln. He added The PYROSCAN camera enabled us to reinforce the kiln monitoring tools and to better control the flame quality. Pyroscans data provides a high contribution for the kiln Master system for automated kiln control.

HGH Kiln shell scanner and dual pyrometric cameras

HGH, which is celebrating its 40-year anniversary this year, offers to the Cement Industry high resolution KILNSCAN kiln shell scanners and PYROSCAN cameras for kilns & coolers.

While rotary kilns have been used for more than a century, monitoring a burner remains a challenge, even more so at a time when energy sustainability is so important.

Because of standard fuel restrictions and in order to reduce overall emissions, the use of alternative fuels is constantly increasing, making control of the flame pattern, size and temperature essential for ensuring kiln stability. Continuous monitoring of the kiln shell temperature and the generation of real-time, sharp temperature maps inside kilns and coolers are a key part of this process.

To meet cement producers requirements in this area, HGH has designed its Pyroscan and Kilnscan solutions. While Pyroscan looks at the kiln from the inside, Kilnscan monitors the temperature of the outside of the kiln shell and is located some distance away from it.

Thermal monitoring using Pyroscan

Kiln shell monitoring using Kilnscan

Robust design, high quality components and thorough testing processes have enabled HGH to produce best-in-class thermal monitoring systems.

With more than 1500 thermal systems in use in over 50 countries worldwide, HGH has built up a reputation for high quality, well-engineered and reliable products that integrate the companys in-depth infrared technologies expertise. HGH is committed to providing its customers with high quality support as well as a large range of services to ensure the overall plant performance.

http://www.hgh-infrared.com

Read the article online at: https://www.worldcement.com/special-reports/06042022/247-kiln-shell-temperature-monitoring-and-process-optimisation-at-lafargeholcim-bouskoura-plant-morocco-using-hgh-thermography-solutions/

The rest is here:

24/7 Kiln shell temperature monitoring and Process Optimisation at LafargeHolcim Bouskoura plant, Morocco, using HGH thermography solutions - World...

Growth Hormone Secretagogue Receptor Type 1 Market Global Industry Analysis, Size, Share, Growth Opportunities, Future Trends, Covid-19 Impact, SWOT…

The global Global growth hormone secretagogue receptor type 1 market focuses on encompassing major statistical evidence for the Global growth hormone secretagogue receptor type 1 market industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition, the Global growth hormone secretagogue receptor type 1 market study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked.

This intelligence and 2026 forecasts Global growth hormone secretagogue receptor type 1 market industry report further exhibits a pattern of analysing previous data sources gathered from reliable sources and sets a precedent growth trajectory for the Global growth hormone secretagogue receptor type 1 market. The report also focuses on a comprehensive market revenue streams along with growth patterns, analytics focused on market trends, and the overall volume of the market.

Get PDF Sample of Global growth hormone secretagogue receptor type 1 market Report @ https://www.contrivedatuminsights.com/request-sample/49101

The Global growth hormone secretagogue receptor type 1 market study further highlights the segmentation of the Global growth hormone secretagogue receptor type 1 market industry on a global distribution. The report focuses on regions of North America, Europe, Asia, and the Rest of the World in terms of developing business trends, preferred market channels, investment feasibility, long term investments, and environmental analysis. The Global growth hormone secretagogue receptor type 1 market report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast.

In addition, the Global growth hormone secretagogue receptor type 1 market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Global growth hormone secretagogue receptor type 1 market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.

The study encompasses a variety of analytical resources such as SWOT analysis and Porters Five Forces analysis coupled with primary and secondary research methodologies. It covers all the bases surrounding the Global growth hormone secretagogue receptor type 1 market industry as it explores the competitive nature of the market complete with a regional analysis.

TABLE OF CONTENTS

Chapter 1. Executive Summary

Chapter 2. Research Methodology

Chapter 3. Market Outlook

Chapter 4. COVID-19 Impact On Global growth hormone secretagogue receptor type 1 market

Chapter 5. Global Global growth hormone secretagogue receptor type 1 market Overview, By Application, 2015 2027(USD Million)

Chapter 6. Global Global growth hormone secretagogue receptor type 1 market Overview, By Distribution Channel, 2015 2027(USD Million)

Chapter 7. Global Global growth hormone secretagogue receptor type 1 market Overview, By Geography, 2015 2027(USD Million)

Chapter 8. North America Global growth hormone secretagogue receptor type 1 market Overview, By Countries, 2015 2027(USD Million)

Chapter 9. Europe Global growth hormone secretagogue receptor type 1 market Overview, By Countries, 2015 2027(USD Million)

Chapter 10. Asia Pacific Global growth hormone secretagogue receptor type 1 market Overview, By Countries, 2015 2027 (USD Million)

Chapter 11. Middle East & Africa Global growth hormone secretagogue receptor type 1 market Overview, By Countries, 2015 2027 (USD Million)

Chapter 12. South America Global growth hormone secretagogue receptor type 1 market Overview, By Countries, 2015 2027 (USD Million)

Chapter 13. Competitive Landscape

Chapter 14. Key Vendor Analysis

Chapter 15. Global growth hormone secretagogue receptor type 1 market Cost Analysis

Chapter 16. Sourcing Strategy and Downstream Buyers

Chapter 17. Marketing Strategy Analysis, Distributors/Traders

Chapter 18. Market Effect Factors Analysis

Chapter 19. Future Outlook of the Market

Reasons to Buy the Report:

Buy Global growth hormone secretagogue receptor type 1 market Report @ https://www.contrivedatuminsights.com/buy/49101

About Us:

Envisage Market Research is the leading provider of custom and syndicated market research reports. Our team of expert analysts offers end-to-end consulting services, along with 80% of the Fortune 500+ companies in the recent past. We are focused to deliver market research report solutions to small and medium enterprises.

Envisage Market Research has steadily grown to become a trusted market research partner for clients across the globe. We are majorly focused to serve a wide range of industrial insights, including automotive & transportation, technology, consumer products, automation and equipment, food & beverages, services & utilities, chemicals & materials, energy, mining, and oil & gas.

Contact Us:Envisage Market ResearchEmail: [emailprotected]

See the article here:

Growth Hormone Secretagogue Receptor Type 1 Market Global Industry Analysis, Size, Share, Growth Opportunities, Future Trends, Covid-19 Impact, SWOT...

Endocrine Disruption Screening Market Growth Sturdy at 2.8 % CAGR to Outstrip USD 153.30 Million by 2028 COVID-19 Impact and Global Analysis by The…

Growing Prevalence of Endocrine Disorders Drives Endocrine Disruption Screening Market Growth

The endocrine disruption screening market is projected to reach US$ 153.30 million by 2028 from US$ 126.53 million in 2021; it is expected to grow at a CAGR of 2.8% during 2021 to 2028.

According to our new research study on Endocrine Disruption Screening Market Forecast to 2028 COVID-19 Impact and Global Analysis by Assay Type, Application, Source of Waste, Method, End-User and Geography. The report highlights trends prevailing in the market and factors driving its growth. The growth of the market is attributed to the growing research in the biotechnology sector and the rising prevalence of endocrine disorders. However, the high cost of screening technology hampers the market growth.

Get Sample PDF Copy of Endocrine Disruption Screening Market at: https://www.theinsightpartners.com/sample/TIPRE00025912/

Acromegaly (overproduction of growth hormone), obesity, metabolic syndrome, impaired fasting glucose, impaired glucose tolerance, osteoporosis, osteopenia, mild-moderate hypovitaminosis D, erectile dysfunction, dyslipidemia, and thyroiditis are among the endocrine disorders that have a collective prevalence of at least 5% among the adults in the US. Of these conditions, Males have the highest incidence of erectile dysfunction, while females have the highest incidence of osteopenia/osteoporosis. Diabetes mellitus in children and pituitary adenoma are the least common conditions, affecting less than 1% of the US population. Adrenocortical carcinoma, pheochromocytoma, and pituitary adenomas are the conditions with the lowest incidence. Hyperparathyroidism and thyroid disorders are more common in women. Diabetes mellitus is most prevalent among ethnic minorities. Endocrine and metabolic diseases are among the most common modern human ailments, particularly in the US and other countries implementing ample nutrition and screening programs for high-risk individuals. Endocrine disorders such as hyperparathyroidism, primary and secondary hypogonadism, GH deficiency, and hypothyroidism can lead to other disorders, such as metabolic bone disease and diabetes mellitus. Thus, the growing prevalence and incidence of such conditions propel the demand for endocrine disruption screening products.

North America held the largest share of the global endocrine disruption screening market in 2021. The US held the largest share of the North American market in 2021. The US market is expected to grow in the coming years due to the increasing adoption of technological advancements and the rising emphasis on the assessment of endocrine disruptor chemicals in agriculture pesticide use, sewage treatment plants, cosmetics and many other fields.

Impact of COVID-19 Pandemic on Endocrine Disruption Screening Market

The COVID-19 pandemic is adversely affecting industries worldwide. The outbreak led to significant disruptions in primary industries, such as manufacturing, healthcare, energy & power, electronics & semiconductor, aerospace & defense, and construction in 2020. The pandemic had a negative impact on the total sales of most companies, whereas it had a favorable impact on the endocrine disruption screening market due to the increased usage of endocrine disruption screening technologies for various hormonal disorders. The lockdown due to the COVID-19 pandemic has forced people to put off getting their hormonal health checked, thus affecting the number of tests being performed and sales of screening products. Due to the COVID-19 pandemic, dealing with hormonal and mental health has become a major medical concern across the world.

Have Question? Speak to Analyst at: https://www.theinsightpartners.com/speak-to-analyst/TIPRE00025912

Creative Bioarray; Charles River Laboratories, Inc; Eurofins Scientific; Alpha Analytical, Inc.; JRF Global; Xenometrix AG; SGS SA; Smithers; and Mrieux NutriSciences are among the leading companies in the endocrine disruption screening market.

The endocrine disruption screening market, by assay type, is bifurcated into in-vitro and in-vivo. Based on application, the market is bifurcated into natural materials and synthetic materials. Based on source of waste, the endocrine disruption screening market is segmented into incineration and landfill, agricultural runoff, industrial and municipal effluents, pulp mill effluents, consumer products, and others. Based on method, the market is segmented into estrogen receptor (ER) transactivation, androgen receptor (AR) transactivation, androgen receptor (AR) modulation, estrogen receptor-alpha (ER) binding, estrogen receptor beta (ER) binding, androgen receptor (AR) binding, steroidogenesis, aromatase assay, and others. Based on end user, the endocrine disruption screening market is segmented into pharmaceutical and biopharmaceutical companies, cosmetics and household product companies, food industry, and chemical industry. By geography, the endocrine disruption screening market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East and Africa (the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East and Africa), and South and Central America (Brazil, Argentina, and the Rest of South and Central America).

Global metabolomics market players and research institutes are constantly involved in activities to study the various aspects of metabolomics to extend its range of applications. The pharmaceuticals, biotechnological, and other companies outsource several processes to reduce cost and produce results in less time. The research and development (R&D) process plays a crucial role in the growth of these businesses. For pharmaceuticals and biotech companies, R&D is necessary for the development of new molecules with greater medical and commercial potential for various therapeutic applications. The companies invest majorly in R&Ds with the aim of delivering high-quality and innovative products to the market. Metabolomics is widely used by these players as part of their development processes, and they opt for outsourcing the metabolomics studies to CROs offering these services. Following are the recent R&D investments made by a few international pharmaceutical and biotechnology companies.

Order a Copy of Endocrine Disruption Screening Market Shares, Strategies and Forecasts to 2028 Research Report at:https://www.theinsightpartners.com/buy/TIPRE00025912/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person:Sameer Joshi

E-mail: [emailprotected]

Phone:+1-646-491-9876

Press Release: https://www.theinsightpartners.com/pr/endocrine-disruption-screening-market

See the original post:

Endocrine Disruption Screening Market Growth Sturdy at 2.8 % CAGR to Outstrip USD 153.30 Million by 2028 COVID-19 Impact and Global Analysis by The...

Former UFC fighter Chael Sonnen being charged with 11 counts of battery over December incident in Las Vegas – ESPN

Retired UFC fighter Chael Sonnen is being charged with 11 counts of battery, including a felony, stemming from a Dec. 18 incident in Las Vegas, according to court records. The felony is being classified as battery by strangulation.

Sonnen initially received five battery citations in the case, but those were dismissed in January without prejudice, which means the charges can be refiled. A new criminal complaint was filed by the Clark County district attorney with the Las Vegas Justice Court on March 16, according to court records.

Sonnen currently works as an MMA analyst for ESPN. "Chael will not appear on ESPN as we explore the details of these serious charges," the company said in a statement.

Sonnen's first court appearance is scheduled for April 27. He did not immediately respond to a request for comment.

The criminal complaint filed against Sonnen and obtained by ESPN says six people were attacked, including a man he is accused of strangling. The complaint states that Sonnen allegedly used "force of violence upon" a woman "by punching/striking" and pushing her.

Sonnen, according to the complaint, allegedly punched the first man, punching and kicking a second man, punching a third man in the face, punching and kneeing a fourth man and striking a fifth man with his elbow.

Documents explaining the details of the situation have yet to be released by the court or the Las Vegas Metropolitan Police Department. A public records request from ESPN was denied by police Wednesday because the case is considered an open and active investigation.

Sonnen, 44, is a former multiple-time UFC title challenger, most known for his rivalry with longtime former middleweight champion Anderson Silva. He was one of the most popular and well-paid fighters of his era, a perennial 185-pound contender and charismatic antagonist to the UFC's biggest stars. Sonnen is a former wrestling All-American at the University of Oregon.

The Oregon native was suspended two years by the Nevada State Athletic Commission for testing positive for several performance-enhancing drugs, including human growth hormone (HGH) and erythropoietin (EPO). It was his third positive drug test in MMA.

Sonnen never returned to the UFC after the suspension, signing with Bellator. He retired from MMA competition in 2019 and has worked for multiple promotions and media outlets as an analyst.

Go here to see the original:

Former UFC fighter Chael Sonnen being charged with 11 counts of battery over December incident in Las Vegas - ESPN